Abstract:Yuequn Song, 1, 2 Lifang Meng, 3 Jian Yu, 1 Zhi Cao, 1 Jizhou Sun, 1 Hongyu Zhao 2 1 Department of Neurosurgery, the Fourth Affiliated Hospital of China Medical University, Shenyang, People's Republic of China; 2 Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China; 3 Department of Scientific Research, China Medical University, Shenyang, People's Republic of China Correspondence: Hongyu Zhao Department of Neurosurgery, Shengjing Hospital of China Medical University, 36 Sanhao St, Heping District, Shenyang, Liaoning, 110004, People's Republic of China Tel +86 18900912293 Email Objective: Tripartite motif 66 (TRIM66) is reported to be closely associated with human cancers. However, the roles of TRIM66 in glioma remain unclear. The present study aimed to investigate the clinical significance and biological roles of TRIM66 in human glioma. Methods: TRIM66 expression in glioma tissues was examined by immunohistochemistry. TRIM66 overexpression and siRNA knockdown were performed in glioblastoma cell lines. CCK8, colony formation assay, transwell assay, Annexin V and JC1 staining, glucose uptake assay, and Western blotting were used to explore the biological roles and potential underlying mechanisms of TRIM66 in glioma progression. Results: Our results showed that TRIM66 was overexpressed in 52/95 glioma cases. The rates of TRIM66 overexpression in Grade I, Grade II, Grade III, and Grade IV gliomas were 16.6%, 41.3%, 58.6%, and 70.9%, respectively. Oncomine data showed that TRIM66 was upregulated in glioblastoma and oligodendroglioma compared with normal brain tissues. TRIM66 expression was higher in glioblastoma cell lines compared with normal SVG p12 glial cell line. TRIM66 promoted in vitro and in vivo proliferation, invasion, and inhibited temozolomide (TMZ)-induced apoptosis. Notably, TRIM66 increased glucose metabolism by upregulating glucose uptake, glucose consumption, and ATP production. Western blotting showed that TRIM66 positively regulated cMyc and GLUT3. Depletion of cMyc by siRNA abolished the effect of TRIM66 on GLUT3. Chromatin immunoprecipitation (ChIP) assay showed that cMyc could bind to the promoter regions of GLUT3 in glioblastoma cells. Conclusion: TRIM66 was upregulated in human gliomas, where it promoted cell growth and chemoresistance. Our data also identified novel roles of TRIM66 in glioma progression. TRIM66 upregulates glucose uptake and mitochondrial function through the cMyc/GLUT3 signaling, which makes it a potential therapeutic target. Keywords: TRIM66, glioma, cMyc, GLUT3 Glioma is the most common malignant tumor in the central nervous system. Despite the improvement in earlier diagnosis, surgery, and chemotherapy, the prognosis for this malignancy remains poor. 1 Overexpression of oncogenes plays a vital role in the development and progression of human glioma and identifying molecular targets in tumor progression is an important task. 2 , 3 Tripartite motif (TRIM) superfamily proteins, most of which have E3 ubiquitin ligase activities and characterized by conserved tripartite motif (TRIM), exhibit various cellular functions and biological processes including transcription regulation, intracellular signaling, cell growth, apoptosis, innate immunity, autophagy, developmental processes, and carcinogenesis. 4–6 Tripartite motif 66 (TRIM66) is a member of the TRIM family which possesses potential functions as a transcriptional repressor. 7 TRIM66 has emerged as an oncogenic protein that is closely related to multiple malignant tumors. In hepatocellular carcinoma (HCC), overexpression of TRIM66 promoted cell proliferation and invasion. 8 TRIM66 activated Wnt signaling by increasing glycogen synthase kinase-3β (GSK-3β) phosphorylation and β-catenin expression. 8 TRIM66 deficiency suppressed cell viability, proliferation, migration, and invasion in prostate cancer cells, possibly through regulation of STAT2/IL-2 signaling. 9 These studies indicated that TRIM66 might function as an oncogenic protein. However, its expression pattern and biological effects in glioma have not been investigated. Here, we investigated the expression pattern of TRIM66 in glioma tissues. We then explored the biological effects of TRIM66 on proliferation, invasion, and TMZ-induced apoptosis in glioma cells. The possible underlying mechanism was also investigated. This study was approved by -Abstract Truncated-

TRIM24 Cooperates with Ras Mutation to Drive Glioma Progression through snoRNA Recruitment of PHAX and DNA‐PKcs

TRIM22 Activates MAPK Signaling by Regulating the Transcription of SPHK2 and Accelerating the Degradation of Raf-1 in Glioblastoma

TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα

TRIM37 interacts with EZH2 to epigenetically suppress PTCH1 and regulate stemness in glioma stem cells through sonic hedgehog pathway

TRIM22 promotes the proliferation of glioblastoma cells by activating MAPK signaling and accelerating the degradation of Raf-1

TRIM21 Overexpression Promotes Tumor Progression by Regulating Cell Proliferation, Cell Migration and Cell Senescence in Human Glioma.

TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3.

TRIM27 promotes the Warburg effect and glioblastoma progression via inhibiting the LKB1/AMPK/mTOR axis

TRIM28 as an independent prognostic marker plays critical roles in glioma progression

TRIM8: a double-edged sword in glioblastoma with the power to heal or hurt

Abstract 5959: Targeting TRIM11 is a potential therapeutic strategy for malignant gliomas

TRIM24 is critical for the cellular response to DNA double-strand breaks through regulating the recruitment of MRN complex

Silencing TRIM6 inhibits the growth and angiogenesis of gliomas by regulating VEGFA

Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner

TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1

Upregulated Tripartite Motif 47 Could Facilitate Glioma Cell Proliferation and Metastasis as a Tumorigenesis Promoter

E3 ubiquitin ligase TRIM21 targets TIF1γ to regulate β-catenin signaling in glioblastoma

TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO

TRIM46 activates AKT/HK2 signaling by modifying PHLPP2 ubiquitylation to promote glycolysis and chemoresistance of lung cancer cells

TRIM44 Activates the AKT/mTOR Signal Pathway to Induce Melanoma Progression by Stabilizing TLR4.

TRIM66 Overexpression Promotes Glioma Progression and Regulates Glucose Uptake Through cMyc/GLUT3 Signaling